title: Phase II trial of gemcitabine in advanced non-small-cell lung cancer.
abstract: Gemcitabine has shown activity in different solid tumors. In the present study we have evaluated its efficacy in 32 patients with advanced non-small-cell lung cancer in a phase II trial. Gemcitabine (1250 mg/m2) was given intravenously as a 30-minute infusion on days 1, 8 and 15. Cycles were repeated every 4 weeks. Twenty-nine patients were evaluable for response and all patients for toxicity. Partial remissions and stable disease were seen in 4 (14%) and 13 (45%) patients, respectively. Improvement of symptoms occurred in 54% of the patients. Side effects were mild and included predominantly leukopenia and thrombocytopenia. In conclusion, gemcitabine is active and well tolerated in patients with advanced non-small-cell lung cancer.
authors.affiliation: Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Malayeri
authors.forename: E
authors.initials: E
authors.lastname: Ulsperger
authors.forename: G
authors.initials: G
authors.lastname: Baumgartner
authors.forename: B
authors.initials: B
authors.lastname: Forstner
authors.forename: K
authors.initials: K
authors.lastname: Aigner
authors.forename: M
authors.initials: M
authors.lastname: Hubner
authors.forename: F
authors.initials: F
authors.lastname: Kummer
authors.forename: G
authors.initials: G
authors.lastname: Krajnik
authors.forename: S
authors.initials: S
authors.lastname: Zöchbauer
authors.forename: K
authors.initials: K
authors.lastname: Krejcy
authors.forename: H
authors.initials: H
authors.lastname: Huber
authors.forename: R
authors.initials: R
authors.lastname: Pirker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001317:Austria; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine